BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 885 filers reported holding BAXTER INTL INC in Q3 2023. The put-call ratio across all filers is 0.40 and the average weighting 0.2%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $751,026 | -21.9% | 19,900 | -5.7% | 0.21% | -17.4% |
| Q2 2023 | $961,316 | +640.7% | 21,100 | +559.4% | 0.26% | +616.7% |
| Q1 2023 | $129,792 | -20.4% | 3,200 | 0.0% | 0.04% | -21.7% |
| Q4 2022 | $163,104 | -100.0% | 3,200 | -55.9% | 0.05% | -64.6% |
| Q3 2022 | $390,485,000 | -17.3% | 7,250 | -1.4% | 0.13% | -10.3% |
| Q2 2022 | $472,090,000 | -35.6% | 7,350 | -22.2% | 0.14% | -24.9% |
| Q1 2022 | $732,753,000 | -9.7% | 9,450 | 0.0% | 0.19% | -4.9% |
| Q4 2021 | $811,188,000 | +3.4% | 9,450 | -3.1% | 0.20% | -5.6% |
| Q3 2021 | $784,192,000 | -6.8% | 9,750 | -6.7% | 0.22% | 0.0% |
| Q2 2021 | $841,225,000 | -6.3% | 10,450 | -1.9% | 0.22% | -10.8% |
| Q1 2021 | $898,221,000 | +0.4% | 10,650 | -4.5% | 0.24% | -3.2% |
| Q4 2020 | $894,676,000 | +19.0% | 11,150 | +19.3% | 0.25% | +6.9% |
| Q3 2020 | $751,927,000 | -20.2% | 9,350 | -14.6% | 0.23% | -19.9% |
| Q2 2020 | $942,795,000 | -2.8% | 10,950 | -8.4% | 0.29% | -22.4% |
| Q1 2020 | $970,221,000 | -2.9% | 11,950 | 0.0% | 0.38% | +26.3% |
| Q4 2019 | $999,259,000 | +0.7% | 11,950 | +5.3% | 0.30% | -8.9% |
| Q3 2019 | $992,785,000 | -13.1% | 11,350 | -18.6% | 0.33% | -0.9% |
| Q2 2019 | $1,142,505,000 | +144.4% | 13,950 | +142.6% | 0.33% | +140.1% |
| Q1 2019 | $467,533,000 | +16.4% | 5,750 | -5.7% | 0.14% | +5.4% |
| Q4 2018 | $401,502,000 | -5.3% | 6,100 | +10.9% | 0.13% | +10.2% |
| Q3 2018 | $423,995,000 | -87.9% | 5,500 | -88.4% | 0.12% | -88.4% |
| Q2 2018 | $3,507,400,000 | +13.5% | 47,500 | 0.0% | 1.02% | +13.7% |
| Q1 2018 | $3,089,400,000 | -5.5% | 47,500 | -6.1% | 0.90% | +0.1% |
| Q4 2017 | $3,270,784,000 | -40.1% | 50,600 | -55.9% | 0.90% | -6.3% |
| Q3 2016 | $5,463,814,000 | +5.0% | 114,786 | -0.2% | 0.96% | +5.4% |
| Q2 2016 | $5,201,928,000 | +14.2% | 115,036 | +3.8% | 0.91% | +7.1% |
| Q1 2016 | $4,553,718,000 | +24.7% | 110,850 | +15.8% | 0.85% | +34.7% |
| Q4 2015 | $3,652,863,000 | +0.1% | 95,750 | -13.8% | 0.63% | +31.4% |
| Q3 2015 | $3,647,993,000 | -24.1% | 111,050 | +61.5% | 0.48% | -10.7% |
| Q2 2015 | $4,807,688,000 | +3.1% | 68,750 | +1.0% | 0.54% | +3.3% |
| Q1 2015 | $4,661,425,000 | +21.0% | 68,050 | +29.5% | 0.52% | +4.0% |
| Q4 2014 | $3,851,390,000 | +1.0% | 52,550 | -1.1% | 0.50% | -6.7% |
| Q3 2014 | $3,814,576,000 | -4.5% | 53,150 | -3.8% | 0.53% | -0.9% |
| Q2 2014 | $3,994,575,000 | -2.4% | 55,250 | -0.7% | 0.54% | -3.6% |
| Q1 2014 | $4,094,727,000 | +33.0% | 55,650 | +25.8% | 0.56% | +18.4% |
| Q4 2013 | $3,077,588,000 | +4.0% | 44,250 | -1.8% | 0.47% | -2.1% |
| Q3 2013 | $2,959,335,000 | -3.5% | 45,050 | +1.8% | 0.48% | -8.4% |
| Q2 2013 | $3,065,197,000 | – | 44,250 | – | 0.53% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SECTOR GAMMA AS | 713,500 | $49,895,000 | 12.74% |
| Veritas Asset Management LLP | 7,636,450 | $534,017,000 | 7.53% |
| FIRST NEW YORK SECURITIES LLC /NY | 154,158 | $10,780,269,000 | 5.40% |
| Gabalex Capital Management LLC | 200,000 | $14,981,000 | 5.39% |
| Veritas Investment Management LLP | 291,825 | $18,816,000 | 5.32% |
| Tweedy, Browne Co LLC | 2,543,966 | $177,900,000 | 4.91% |
| York Capital Management Global Advisors, LLC | 8,074,375 | $564,641,000 | 4.78% |
| First Fiduciary Investment Counsel, Inc. | 270,675 | $18,928,000 | 4.10% |
| SCHARF INVESTMENTS, LLC | 2,247,225 | $157,148,000 | 4.03% |
| Osher Van de Voorde Investment Management | 96,235 | $6,730,000 | 3.91% |